Physician profile
Deborah Fein
NPI 1891007530
$2,430.46
in general payments reported to CMS, 2019-2025
15 companies · $720 in 2025
The $720 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.84 · 2020: $81.73 · 2021: $306 · 2022: $133 · 2023: $646 · 2024: $472 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $669.88 | 2021-2025 | |
| Lundbeck LLC | $373.07 | 2020-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $277.79 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $274.49 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $199.94 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $159.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $102.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.63 | 2025 | Caplyta |
| Bausch Health US, LLC | $67.95 | 2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $47.32 | 2022-2023 | Invega Trinza, Invega Sustenna |
| Shire North American Group INC | $41.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.46 | 2023 | Austedo Xr |
| Neuronetics, INC. | $35.98 | 2023 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $21.47 | 2021 | |
| Noven Therapeutics, LLC | $21.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.